A Comparison of Depressive Symptom Self-Reported Measures in the Texas Youth Depression and Suicide Research Network (TX-YDSRN)

Major depressive disorder (MDD) is a heterogeneous, prevalent syndrome that affects persons of all ages, including 3% of 3-to 17-year-olds.¹ In youth, MDD is often associated with substantial functional impairment and mortality.^2–5 Antidepressant medications and evidence-based psychotherapies have demonstrated efficacy in clinical research trials.⁶ Suboptimal outcomes in practice, however, can result from underrecognition and undertreatment.^7–9

Depressive symptom rating scales such as the Children’s Depression Rating Scale (CDRS)¹⁰ or the Patient Health Questionnaire (PHQ),¹¹ when used as screening instruments, can address underrecognition. Undertreatment has been addressed in research studies with frequent visits and diligent dose escalation informed by the regular clinical ratings of depressive symptoms with global or itemized depressive symptom measures such as the CDRS, Montgomery-Šsberg Depression Rating Scale,¹² or Hamilton Depression Rating Scale.¹³ In practice, undertreatment has been addressed with less time-consuming self-reported depression ratings (Patient Reported Outcomes [PROs])¹⁴ to inform clinical decision-making or to implement measurement-based care (MBC).^15–21 Recent practice guidelines suggest that MBC is underutilized in practice, despite evidence for its effectiveness.⁶

Practitioners rely on PROs to assess outcomes or implement MBC, while researchers often report PROs as secondary outcomes, relying on clinician-rated scales for primary outcomes. Research findings may be more readily understood and applied in practice sooner if they could be converted into metrics that clinicians use.²² The linkage of different instruments that measure the same construct to a common metric by cocalibrating item parameters is known as a crosswalk. Indeed, some studies with adult depressed patients have provided crosswalks between total scores on clinical and self-reported ratings.²³ Crosswalks between total scores on various PROs should help clinicians, services researchers, and care system managers compile screening and outcome data collected with various PROs from different care systems. Crosswalks between standard and even briefer PROs are also being developed to facilitate their use in smartphones to more frequently gather clinical information. Frequent measurements may be necessary to assess outcomes of difficult-to-treat depression,^24,25 in which symptoms are expected to wax and wane over time. For example, the brief 5-item Very Quick Inventory of Depressive Symptomatology-Self-Report (VQIDS-SR₅)^26,27 was developed to provide a convenient clinical tool that could be crosswalked back to the 16-item self-reported Quick Inventory of Depressive Symptomatology (QIDS-SR₁₆),²⁵ which itself is a subset of the Inventory of Depressive Symptomatology¹⁵ (Supplementary Table 1).

To address some of the knowledge gaps among several PROs, this report psychometrically compared and developed crosswalks among 3 patient-reported assessments measuring depressive symptoms in a sample of adolescents and young adults from the Texas Youth Depression and Suicide Research Network (TX-YDSRN).²⁸ Specifically, it evaluates and compares the PHQ-A²⁹ (the adolescent version of the 9-item PHQ), QIDS-SR₁₆,^18,19 and VQIDS-SR₅.^25,26 We were interested in whether the brief VQIDS-SR₅ can provide a reasonable bridge between the longer QIDS-SR₁₆, which is more commonly used in research, and PHQ-A, a standard in clinical practice.

Specifically, the following research questions were addressed:

1. Do these 3 scales have comparable measures of internal consistency?
2. Are these scales unidimensional, measuring the same trait?
3. How do individual items perform in relation to the overall trait in each scale?
4. Can the scale total scores be linked, so that the total score on each scale can be converted to those of the others?
5. How do the 3 scales compare to each other in detecting change between baseline and 1-month follow-up assessments?

METHODS

Study Design and Participants

Launched in August 2020, the TX-YDSRN consists of 12 academic medical institutions in Texas that contribute to a registry of children and adolescents (ages 8 to 20 years) with a positive screening for depression or suicidal ideation or behavior or who are actively receiving treatment for depression at participating clinics. Ineligibility criteria included having active psychotic symptoms or acute medical or psychological condition(s) that would make participation difficult or unsafe. We did not assess personality disorder or autism spectrum disorder diagnoses as part of this study. We also did not test for IQ, although if there were concerns about the cognitive ability of a participant to complete the forms/measures, they were excluded. Details about the TX-YDSRN and further characterization of the sample can be found elsewhere.²⁸ This report focuses exclusively on depressed adolescents, ages 12–20 (n = 795), who were enrolled and completed their baseline visit between August 26, 2020, and May 11, 2022.

Measures

Demographic characteristics (ie, age, race, Hispanic ethnicity, and sex assigned at birth) were based on self-report.

Patient Health Questionnaire for Adolescents (PHQ-A). The PHQ-A is a 9-item self-report questionnaire²⁹ that measures the past-2-weeks prevalence of each of the 9 criterion symptoms that define a major depressive episode according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5),³⁰ with rephrasing of items from the adult PHQ¹¹ to better suit adolescents. This includes adding irritation to the melancholy mood item 1 and adding schooling to the focus item 7.²⁹ Each item is rated 0–3: 0 (“Not at all”), 1 (“Several days”), 2 (“More than half the days”), and 3 (“Nearly every day”), with total score ranging from 0 to 27 and higher scores indicating more severe depressive symptoms (Supplementary Table 1).

16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR₁₆). The 16-item QIDS-SR₁₆^18,19 was derived from the 30-item IDS-SR,^15,16 which was developed as a measure of depressive symptom severity over the prior 7 days. The 16 items on the QIDS-SR₁₆ were selected from the 30-item Inventory of Depressive Symptomatology Self-Report (IDS-SR) items to assess 9 DSM-IV and DSM-5 criterion symptom domains, which are identical to the 9 domains assessed by PHQ-9 (ie, sad mood; concentration; self-criticism; suicidal ideation; interest; energy/fatigue; sleep disturbance [initial, middle, and late insomnia or hypersomnia]; decrease/increase in appetite/weight; and psychomotor agitation/retardation). The total score on the QIDS-SR₁₆ ranges from 0 to 27 with higher scores indicating more severe depressive symptoms. The QIDS-SR₁₆ is sensitive to change.^18,19,23

5-item Very Quick Inventory of Depressive Symptomatology–Self-Report (VQIDS-SR₅). VQIDS-SR₅ was created out of the QIDS-SR₁₆ as a short, 5-item measure of the core symptoms of depression^25,26 that best match 5 of the 6 items on the 6-item Hamilton rating scale,^31–33 except for anxiety (Supplementary Table 1). The range is from 0 to 15, with higher scores indicating greater depressive symptom severity. It is sensitive to change in adults,²⁶ and crosswalks in adults have been reported.²⁵

Mini-International Neuropsychiatric Interview (MINI)-Kid. The MINI is a structured psychiatric interview that assesses the 30 most common disorders in pediatric mental health.³⁴ In this study, we focused on the “primary diagnosis” using the MINI item, “Which problem troubles you the most or dominates the others or came first in the natural history?” which lists 37 different primary diagnoses. Note that for this question, youth and guardian (if youth was under 18 years old) were interviewed, and the clinician made the assessment of the primary diagnosis. From the responses to this item, we took the following as indicators of depression: major depressive disorder (past 2 weeks/past/recurrent), persistent depressive disorder (current), bipolar I disorder (current and/or past), bipolar II disorder (current and/or past), other specified bipolar and related disorders (current and/or past), bipolar I disorder with psychotic features (current and/or past), and major depressive disorder with psychotic features (current and/or past).

Statistical Data Analyses

Classical test theory was used to assess the internal consistency of each of the 3 scales. Corrected item-total correlations for each item within a scale were calculated. Values > 0.3 indicate that an item discriminates well.³⁵ Next, parallel analysis³⁶ assessed the unidimensionality of each scale. If established, unidimensionality indicates that all items of a scale adhere to a single latent trait and that a “total score” based on summing scale items is a valid representation of that latent trait.

Next, to assess how individual items within each scale perform in relation to the scale’s overall trait, a graded response model,³⁷ which is appropriate for scales with multicategory items such as the QIDS-SR₁₆, VQIDS-SR₅, and PHQ-A, was implemented using MULTILOG.³⁸ In the Samejima model, the “a” parameter represents the ability of the item to distinguish between levels of depression and is closely related to the correlation between the item and total score. The “b” parameters represent locations on the item-response theory (IRT) depression severity scale (theta). Theta is an IRT-based measure of depression severity in standard deviation units where 0 represents average depression severity. Each QIDS-SR₁₆, VQIDS-SR₅, and PHQ-A item has 4 levels which result in 3 location parameters (b₀, b₁, and b₂). The parameter b₀ represents the level of depression at which a subject would be equally likely to endorse 0 versus 1, 2, or 3, while b₁ represents equal likelihood of 0 or 1 versus 2 or 3 and b₂ represents equal likelihood of 0, 1, or 2 versus 3. Higher values of “b” parameters indicate that higher levels of depression are needed for a subject to endorse a given level of that item and imply that the item is less frequently endorsed.

The next goal was to determine whether the total score on each scale could be linked and thus converted to that of the others. Conversion tables were constructed that equate total scores for each pair of scales with equivalent levels of depression severity by computing the IRT score (theta) for each total score of each scale, using the method of Orlando et al³⁹ and equating total scores with the closest IRT scores. The graded IRT model was also used to compute the test information function (TIF) for each scale.⁴⁰ The “test information” provided by a scale is the inverse of the standard error of the total score of the scale. A total score that provides a more precise estimate of symptom severity contains more “information” than a less precise estimate.

Finally, we assessed whether the 3 scales were sensitive to change by (1) calculating percent change between baseline and 1-month follow-up for each total score; (2) calculating the correlation coefficients of these quantities between pairs of scales; and (3) calculating effect sizes for the total score and items in each scale.

RESULTS

The sample consisted of all youth (ages 12–20 years) who completed the PHQ-A and IDS-SR during their baseline visit and had depression as their primary diagnosis based on the MINI (n = 795). Baseline data were used to answer research questions 1–4. For research question 5, 1-month post-baseline visit data were used in addition to the baseline data. Out of the n = 795 eligible youth at baseline, the majority (n = 682) had IDS-SR and PHQ-A data at 1-month follow-up visit. The 113 youth without follow-up data did not differ from those who did by demographic variables (ie, sex, age, race, and ethnicity).

Sample Characteristics

The majority of the analytic sample was White (n = 524, 65.9%), female (n = 595, 74.8%), and Hispanic (n = 427, 54.7%) (Table 1). Distributions of QIDS-SR₁₆ and PHQ-A total scores by domain at baseline are in Supplementary Figure 1.

Classical Test Theory Findings

Standardized Cronbach alphas were 0.86 (PHQ-A), 0.80 (QIDS-SR₁₆), and 0.76 (VQIDS-SR₅). Additionally, the corrected item-total correlation for each scale at baseline varied between 0.49–0.72 (PHQ-A), 0.29–0.64 (QIDS-SR₁₆), and 0.43–0.61 (VQIDS-SR₅) (Table 2).

Dimensionality

For PHQ-A, the first eigenvalue from the sample data (4.35) was larger than the first eigenvalue of the simulated data (1.16), and the second eigenvalue from the sample data was lower than the second eigenvalue of the simulated data (0.996 vs 1.10), demonstrating its unidimensionality. Similar findings were observed for QIDS-SR₁₆ (sample vs simulated eigenvalues: 3.69 vs 1.16; 0.98 vs 1.10) and VQIDS-SR₅ (2.59 vs 1.10; 0.81 vs 1.04).

Item-Response Theory Findings

Table 3 presents the IRT item parameters of the 3 scales. For the QIDS-SR₁₆ and VQIDS-SR₅, the item related to energy/fatigability was most sensitive in distinguishing levels of depression, while “Little interest or loss of pleasure” was most sensitive for the PHQ-A. For QIDS-SR₁₆ and PHQ-A, the suicide ideation item required the greatest severity of depression for endorsement, while for the VQIDS-SR₅, the psychomotor retardation item required the greatest severity of depression. Figure 1 shows that PHQ-A followed by QIDS-SR₁₆ and VQIDS-SR₅ provide the most precise estimates of symptom severity within 2 standard deviations of the average. Table 4 shows the pairwise conversions of total scores between the VQIDS-SR₅ and QIDS-SR₁₆, VQIDS-SR₅ and PHQ-A, and QIDS-SR₁₆ and PHQ-A, respectively.

Are the Scales Sensitive to Change?

Supplementary Figure 2 reveals a strong relationship between QIDS-SR₁₆ total score and VQIDS-SR₅ (r = 0.87, n = 682, P < .0001) in assessing changes in severity between baseline and 1-month follow-up. A modest but significant association was found between baseline to 1-month changes in PHQ-A total score and VQIDS-SR₅ (r = 0.50, n = 682, P < .0001) and between PHQ-A and QIDS-SR₁₆ total scores (r = 0.56; n = 682, P < .0001). Effect sizes for the changes in total scores were 0.45, 0.47, and 0.35 for PHQ-A, QIDS-SR₁₆, and VQIDS-SR₅, respectively. Note that most patients had been in ongoing treatment and would not be expected to change during the 1-month observation period.

DISCUSSION

This report assessed the psychometric properties of the PHQ-A, the QIDS-SR₁₆ and the VQIDS-SR₅ in a large sample of 12- to 20-year-olds who screened positive for depression and/or suicidal ideation or were in treatment for depression. All 3 scales were unidimensional with high internal consistencies (Cronbach alphas from 0.76–0.86). Similar levels of internal consistency were seen between the PHQ-9 and QIDS-SR₁₆ in an adult primary care setting in Singapore⁴¹ (Cronbach α: 0.87 and 0.79, respectively). Also, in an adult sample of 297 depressed inpatients in China, Cronbach α was 0.88 (PHQ-9) and 0.83 (QIDS-SR₁₆).⁴² The corrected item-total correlations among the 3 instruments were also acceptable: 0.49–0.72 (PHQ-A), 0.29–0.64 (QIDS-SR₁₆), and 0.43–0.61 (VQIDS-SR₅). Test information function was highest for PHQ-A and acceptable but lower for the VQIDS-SR₅, as might be expected with a shorter measure.⁴³ All 3 scales were sensitive to change over a 1-month follow-up period.

Thresholds for severity categories were nearly identical for PHQ-A and QIDS-SR₁₆ (ie, 0–5; 5–10; 10–15; 15–20; 20+) as might be expected since each rating assesses the same 9 criterion symptom domains with each rated 0–3 (range of total score being 0–27 on both ratings). When total score changes between baseline and 1-month follow-up were computed for each scale, the correlation between changes in the VQIDS-SR₅ and QIDS-SR₁₆ was, as expected, high since the VQIDS-SR₅ items are included in the QIDS-SR₁₆ total. This finding suggests that VQIDS-SR₅ total score is a reasonable proxy for QIDS-SR₁₆, albeit with less test information. It cannot be used to screen for all 9 criterion symptom domains as can the PHQ-A or the QIDS-SR₁₆. However, a brief assessment may be sufficient when frequent assessment of severity is necessary.

Correlations between changes over the 1-month period in PHQ-A with QIDS-SR₁₆ and VQIDS-SR₅ were modest (range, 0.50–0.56), suggesting that the change in the prevalence of symptoms reflected in the PHQ-A total score over time is not as tightly tied to the change in symptom severity despite measuring the same 9 criterion symptom domains as the QIDS-SR₁₆. This distinction between severity and prevalence is often seen clinically as some persons have a persistent low level of depressive symptoms while others have episodic exacerbations that are impersistent. The expression of disease severity may include both symptom severity and prevalence/pervasiveness, both of which can change over time. A response could entail a reduction in severity, pervasiveness, or both. Frequent sampling of both severity and pervasiveness may add precision not available with the assessment of only one of these parameters.

Of note, the item-total correlations for the sleep and appetite/weight items on the QIDS-SR₁₆ were modest. These results are consistent with a recent report⁴⁴ using the Chinese version of the QIDS-SR₁₆ in a sample of adolescents with major depressive episodes or bipolar depressive episodes, where item-total correlations were found to be the lowest for the sleep and appetite/weight items as well. This contrasts with the PHQ-A findings in this report in which the item-total correlations were not lower for the sleep and appetite items. An examination of these individual PHQ-A and QIDS-SR₁₆ items suggests that the thresholds, which were based on adults, may be less suitable for adolescents. That is, adolescents’ regulation of sleep and appetite may be affected by more than depression (stresses with schoolwork, comorbid conditions such as anxiety, etc). It may be easier to estimate them more accurately, and in ways that are consistent with the overall concept of depression, if the measurement period is over 2 weeks, or if prevalence thresholds are used in place of severity thresholds.

Overall, these findings suggest that any of the 3 measures constitute a satisfactory outcome tool. The VQIDS-SR₅ total score is a time-saving alternative that is highly correlated with the QIDS-SR₁₆ total score. The present crosswalk tables provide reassurance that one can validly convert QIDS-SR₁₆ total to VQIDS-SR₅ total and vice versa. The thresholds identified in this report with younger patients closely approximate those in a prior report that crosswalked the clinician rated VQIDS-C₅ and clinician completed QIDS-C₁₆.²⁵ Specifically, none, mild, moderate, severe, and very severe category thresholds were 0–1, 2–4, 5–8, 9–12, and 13–15, respectively, with the VQIDS-SR₅, while they were 0–2, 3–5, 6–8, 9–12, and 13–15 with the clinician version of the VQIDS-C₅. Item-total correlations ranged from 0.43 to 0.61 in the youth in this report, while they were 0.57–0.74 with adults using the clinician VQIDS-SR₅. This less consistent performance in this report, though certainly satisfactory, could be due to the shift from clinician to patient rating or the younger age of this sample.

Limitations

This report has several limitations. The QIDS-SR₁₆ and VQIDS-SR₅ were derived from the adult IDS-SR, while the PHQ-A was adapted to an adolescent population. Whether a tighter relationship between these measures would have resulted had an adolescent version of the QIDS-SR been used is unknown.⁴⁵ The subjects in this report may have already been receiving treatment for depression at the time of the study, so the modest change between the baseline and 1-month assessments may be a result of ongoing care or the fact that the time assessed was limited to 1 month. Longer observation periods with more measurement occasions would be more informative. In addition, many subjects in the study were already receiving pharmacologic treatments that could have affected sleep, appetite/weight, and other symptoms. These medications could have affected both severity and prevalence of symptoms.

There may be a lack of systematic reporting of the comorbidities and, possibly, underdiagnosis of bipolar disorder within this sample. A few participants of the TX-YDSRN study have a diagnosis of bipolar disorder. Being that participants are young and lacking a long-term follow-up (at the time of the collection of this data), fewer episodes can be observed, and this may limit diagnostic accuracy within this sample for bipolar disorders. Furthermore, juvenile onset depressive episodes represent a major risk factor for diagnosis of bipolar disorder.⁴⁶ There is also evidence on the importance of assessing subsyndromal mixed/manic features in depressive episodes,⁴⁷ which often are correlates of depression severity in adolescence.⁴⁸

It is important to note that the VQIDS-SR₅ does not assess suicidal ideation. Suicidal ideation should be assessed at every visit with all patients receiving psychotropic medications regardless of whether a scale is used or not. Scales administration was not randomized. The PHQ-A was given first, followed by IDS-SR. Completion of one scale could have affected the results of the scale that followed.

CONCLUSION

In summary, PHQ-A, QIDS-SR₁₆, and VQIDS-SR₅ are unidimensional, psychometrically acceptable self-reports that assess depressive symptom burden whether based on severity (QIDS-SR₁₆ and VQIDS-SR₅) or on prevalence (PHQ-A) of the 9 criterion symptom domains that define MDD by DSM-5. They are sensitive to change over time. Most importantly, total scale scores of any measure can be converted to that of any other measure.

Article Information

Published Online: December 18, 2023. https://doi.org/10.4088/JCP.23m14861
© 2023 Physicians Postgraduate Press, Inc.
Submitted: March 13, 2023; accepted September 13, 2023.
To Cite: Nandy K, Rush AJ, Carmody T, et al. A comparison of depressive symptom self-reported measures in the Texas Youth Depression and Suicide Research Network (TX-YDSRN). J Clin Psychiatry. 2024;85(1):23m14861
Author Affiliations: Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas (Nandy, Carmody); Center for Depression Research and Clinical Care, Peter O’Donnell Jr. Brain Institute and the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (Nandy, Carmody, Slater, Mayes, Trivedi); Curbstone Consultant LLC, Santa Fe, New Mexico (Rush); Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina (Rush); Duke-National University of Singapore, Singapore (Rush); Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (Kennard, Emslie); Children’s Medical Center, Dallas, Texas (Kennard, Emslie); University of Texas Medical Branch, Galveston (DeFilippis); Department of Psychiatry, University of Texas Rio Grande Valley, School of Medicine, Edinburg (Garza); Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine Houston Texas (Storch); Department of Psychiatry, Texas Tech University Health Science Center, Lubbock (Wakefield).
Corresponding Author: Madhukar H. Trivedi, MD, Center for Depression Research and Clinical Care, Peter O’Donnell Jr. Brain Institute, Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9119 (madhukar.trivedi@utsouthwestern.edu).
Relevant Financial Relationships: Dr Rush has received consulting fees from Compass Inc., Curbstone Consultant LLC, Emmes Corp., Evecxia Therapeutics, Inc., Holmusk Technologies, Inc., ICON, PLC, Johnson and Johnson (Janssen), Liva-Nova, MindStreet, Inc., Neurocrine Biosciences Inc., Otsuka-US; speaking fees from Liva-Nova, Johnson and Johnson (Janssen); and royalties from Wolters Kluwer Health, Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptomatology and its derivatives). He is named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Dr Carmody has served as a consultant for Alkermes, Inc. Dr Kennard receives royalties from Guilford Press, Inc. and serves on the board of trustees for the Jerry M. Lewis, III, MD Research Foundation. Dr Emslie is a consultant for Lundbeck, Neuronetics, and Otsuka and receives research support from American Foundation for Suicide Prevention, Janssen Research & Development and Pharmaceuticals, National Institutes of Health (NIH), Patient-Centered Outcomes Research Institute, and the State of Texas. Dr Storch receives grant support from NIH, the Ream Foundation, Greater Houston Community Foundation, International OCD Foundation, and Texas Higher Education Coordinating Board; receives book royalties from Elsevier, Springer, American Psychological Association, Jessica Kingsley, Oxford, and Lawrence Erlbaum; was a consultant for Brainsway and Biohaven; and owns stock in NView. Dr Trivedi has provided consulting services to Alkermes Inc, Axsome Therapeutics, Biogen MA Inc., Cerebral Inc., Circular Genomics Inc, Compass Pathfinder Limited, GH Research Limited, Heading Health Inc, Janssen, Legion Health Inc, Merck Sharp & Dohme Corp., Mind Medicine (MindMed) Inc, Merck Sharp & Dhome LLC, Naki Health, Ltd., Neurocrine Biosciences Inc, Noema Pharma AG, Orexo US Inc, Otsuka American Pharmaceutical Inc, Otsuka Canada Pharmaceutical Inc, Otsuka Pharmaceutical Development & Commercialization Inc, Praxis Precision Medicines Inc, SAGE Therapeutics, Sparian Biosciences Inc, Takeda Pharmaceutical Company Ltd, and WebMD; is on the Scientific Advisory Board of Alto Neuroscience Inc, Cerebral Inc., Compass Pathfinder Limited, Heading Health, GreenLight VitalSign6 Inc, Legion Health Inc, Merck Sharp & Dohme Corp, Orexo US Inc, and Signant Health; holds stock in Alto Neuroscience Inc, Cerebral Inc, Circular Genomics Inc, GreenLight VitalSign6 Inc, and Legion Health Inc; and has received editorial compensation from American Psychiatric Association and Oxford University Press. Drs Nandy, Slater, Mayes, DeFilippis, Garza, and Wakefield do not have any conflicts to declare.
Funding/Support: This manuscript was funded by the Texas Youth Depression and Suicide Research Network (TX-YDSRN), a research initiative of the Texas Child Mental Health Care Consortium (TCMHCC). The TCMHCC was created by the 86th Texas Legislature and, in part, funds multi-institutional research to improve mental health care for children and adolescents in Texas. The content is solely the responsibility of the authors and does not necessarily represent the official views of the various funding organizations.
Role of the Funders/Sponsors: The funding source had no role in the design, collection, analysis, or interpretation of the data.
Disclaimer: The Intellectual Property of TX-YDSRN belongs to the University of Texas Southwestern Medical Center (Principal Investigator, Dr Trivedi).
Acknowledgments: The authors thank the patients, clinics, staff, and colleagues who made this project possible. They acknowledge the TX-YDSRN teams from the following sites: University of Texas Southwestern Medical Center, Baylor Medical Center, Texas A&M University System Health Science Center, Texas Tech University Health Science Center Lubbock, Texas Tech University Health Science Center El Paso, University of Texas at Austin Dell Medical School, University of Texas Health San Antonio, University of Texas Rio Grande Valley, University of Texas Health Science Center Houston, University of Texas Health Science Center Tyler, University of Texas Medical Branch, and University of North Texas Health Science Center.
Licensing of QIDS-SR₁₆ and VQIDS-SR₅: Licensing and distribution of QIDS-SR₁₆ and VQIDS-SR₅ are managed by Mapi Research Trust on behalf of the copyright holder, University of Texas Southwestern Medical Center. Requests for information and licensing of QIDS-SR₁₆ and VQIDS-SR₅ should be submitted through Mapi Research Trust’s ePROVIDE platform (https://eprovide.mapi-trust.org/).
Supplementary Material: Available at Psychiatrist.com.

CLINICAL POINTS

• Three patient-reported outcomes—Patient Health Questionnaire for Adolescents (PHQ-A), Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR₁₆), and Very Quick Inventory of Depressive Symptomatology–Self-Report (VQIDS-SR₅)—can be used to assess depressive symptom severity and change over time in 8- to 20-year-olds.
• PHQ-A and QIDS-SR₁₆ total scores are approximately the same.
• Severity thresholds on PHQ-A are approximately matched to VQIDS-SR₅ total scores of 0–1 (none), 2–4 (mild), 5–7 (moderate), 8–10 (severe), and 11+ (very severe).